Effects of novel chalcone derivatives on α-glucosidase, dipeptidyl peptidase-4, and adipocyte differentiation in vitro
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Chana series are new chalcone derivatives. To evaluate the possibility of Chana series as therapeutic agents of type 2 diabetes,the inhibitory effects of Chana series on the activities of α-glucosidase and DPP-4 were investigated using in vitro enzyme assays, and their effects on adipocyte differentiation were investigated in C3H10T1/2 cells. Chana 1 and Chana 7among the Chana series showed significant inhibition of α-glucosidase activity. In DPP-4 enzyme assay, Chana 1 exhibited the highest inhibitory activity while Chana 7 did not. In MTT assay, Chana 1 did not show significant cytotoxicity up to a concentration of 250 μM, whereas cytotoxicity was observed with Chana 7 at a concentration of 300 μM. In addition,Chana 1 induced adipocyte differentiation. Therefore, Chana 1showed inhibitory effects on α-glucosidase and DPP-4 as well as a stimulatory effect on adipocyte differentiation, suggesting that Chana 1 may be a potential beneficial agent for the treatment of type 2 diabetes. [BMB reports 2011; 44(6): 410-414]
Abstract
Chana series are new chalcone derivatives. To evaluate the possibility of Chana series as therapeutic agents of type 2 diabetes,the inhibitory effects of Chana series on the activities of α-glucosidase and DPP-4 were investigated using in vitro enzyme assays, and their effects on adipocyte differentiation were investigated in C3H10T1/2 cells. Chana 1 and Chana 7among the Chana series showed significant inhibition of α-glucosidase activity. In DPP-4 enzyme assay, Chana 1 exhibited the highest inhibitory activity while Chana 7 did not. In MTT assay, Chana 1 did not show significant cytotoxicity up to a concentration of 250 μM, whereas cytotoxicity was observed with Chana 7 at a concentration of 300 μM. In addition,Chana 1 induced adipocyte differentiation. Therefore, Chana 1showed inhibitory effects on α-glucosidase and DPP-4 as well as a stimulatory effect on adipocyte differentiation, suggesting that Chana 1 may be a potential beneficial agent for the treatment of type 2 diabetes. [BMB reports 2011; 44(6): 410-414]
참고문헌 (24)
- Zimmet, P, "Global and societal implications of the diabetes epidemic", Nature, 414, pp.782~787 (2001)
- Astrup, A, "Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'", Obes. Rev, 1, pp.57~59 (2000)
- Kahn, B. B, "Obesity and insulin resistance", J. Clin. Invest, 106, pp.473~481 (2000)
- Syiem, D, "Hypoglycemic effects of Potentilla fulgens L in normal and alloxan-induced diabetic mice", J. Ethnopharmacol, 83, pp.55~61 (2002)
- Ratner, R. E, "Controlling postprandial hyperglycemia", Am. J. Cardiol, 88, pp.26H~31H (2001)
- Caspary, W. F, "Sucrose malabsorption in man after ingestion of alpha-glucosidehydrolase inhibitor", Lancet, 1, pp.1231~1233 (1978)
- Lebovitz, H. E, "alpha-Glucosidase inhibitors", Endocrinol. Metab. Clin. North. Am, 26, pp.539~551 (1997)
- Youn, J. Y, "Anti-hyperglycemic activity of Commelina communis L.: inhibition of alpha-glucosidase", Diabetes Res. Clin. Pract, 66(Suppl 1), pp.S149~S155 (2004)
- Li, Y, "Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats", J. Ethnopharmacol, 99, pp.239~244 (2005)
- Creutzfeldt, W, "New developments in the incretin concept", Diabetologia, 28, pp.565~573 (1985)
- Zander, M, "Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study", Lancet, 359, pp.824~830 (2002)
- Drucker, D. J, "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368, pp.1696~1705 (2006)
- Deacon, C. F, "Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects", Diabetes, 44, pp.1126~1131 (1995)
- Deacon, C. F, "Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs", Diabetes, 50, pp.1588~1597 (2001)
- Park, W. J, "Effect of epibrassinolide on hypocotyl growth of the tomato mutant diageotropica", Planta, 207, pp.120~124 (1998)
- Haraguchi, H, "Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata", Bioorg Med. Chem, 6, pp.339~347 (1998)
- Haraguchi, H, "Mode of antibacterial action of retrochalcones from Glycyrrhiza inflata", Phytochemistry, 48, pp.125~129 (1998)
- Maeda, N, "PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein", Diabetes, 50, pp.2094~2099 (2001)
- Staels, B, "Therapeutic roles of peroxisome proliferator-activated receptor agonists", Diabetes, 54, pp.2460~2470 (2005)
- Cho, K. W, "and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARgamma transcriptional activity", J. Nutr. Biochem, 21, pp.841~847 (2010)
- Shin, D. W, "(-)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation", BIOCHEMICAL PHARMACOLOGY, 77(1), pp.125~133 (2009), PERGAMON-ELSEVIER SCIENCE LTD
- Tanaka-Amino, K, "ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity", Eur. J. Pharmacol, 590, pp.444~449 (2008)
- Lee, J. S, "Heparin-binding epidermal growth factor-like growth factor inhibits adipocyte differentiation at commitment and early induction stages", Differentiation, 76(5), pp.478~487
- Bak, E. J, "Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes", Int. J. Obes, 34, pp.250~260 (2010)